EVA, Metabolic Syndrome and rehabilitation
|
|
- Jasmine Lawrence
- 5 years ago
- Views:
Transcription
1 Baltic Rehab Congress Tallinn 17th September 2010 EVA, Metabolic Syndrome and rehabilitation Peter Nilsson, MD, PhD Department of Clinical Sciences Lund University University Hospital, Malmo, Sweden
2 Metabolic syndrome Genes Lifestyle Increased risk of: cardiovascular disease, PCO type-2 diabetes, cognitive decline
3 Early Vascular Ageing (EVA): Atherosclerosis and arterial stiffening Foam Cells Fatty Streak Intermediate Lesion Atheroma Fibrous Plaque Complicated Lesion/Rupture Endothelial Dysfunction From First Decade From Third Decade From Fourth Decade Growth of the Lipid Core Smooth Muscle and Collagen Thrombosis Nilsson PM, et al. J Hypertens 2008, Hypertension 2009 Minamino T, Circ Res 2007;100;15-26
4 Gerald Reaven, Banting Lecture 1988
5 Kylin E. Studien über das Hypertonie- Hyperglykemie- Hyperurikemiesyndrom. Zentralblatt für Innere Medizin 1923;7:105 Eskil Kylin ( ) Sarafidis P, Nilsson PM. J Hypertens 2005
6 Cornerstones in the Insulin Resistance Syndrome (IRS) or MetS Glucose visceral obesity hypertension liver steatosis dyslipidemia Insulin resistance endothelial dysfunction chronic inflammation Free Fatty Acids heredity (genes) lifestyle Insulin
7 Cumulative Hazard (%) Adverse Prognostic Implications of Cardiovascular Metabolic Syndrome Population-based observational study in 1209 men Metabolic syndrome present Metabolic syndrome absent Coronary heart disease mortality Cardiovascular disease mortality All-cause mortality RR (95% CI): 3.77 ( ) RR (95% CI): 3.55 ( ) RR (95% CI): 2.43 ( ) No. at risk metabolic syndrome Yes No Follow-up (years) Follow-up (years) Follow-up (years) Lakka H-M et al. JAMA. 2002;288:
8 The Metabolic syndrome: Time for a critical appraisal Joint Statement from the American Diabetes Association and the European Association for the Study of Diabetes Kahn R, Buse J, Ferrannini E, Stern M. Diabetes Care 2005;28:
9 New joint definition of MetS in 2009 Harmonizing the Metabolic Syndrome Based on the occurrence of three or more out of five of these risk factors: Elevated waist: population-specific cut-off levels Increased blood pressure: 130/85 mmhg Elevated glucose: 5.6 mmol/l Dyslipidaemia: Tg 1.7 mmol/l; HDL-C 1.0 in men and 1.3 mmol/l in women No priority for waist circumference alone Waist limits should be modified when applied to different ethnical groups Alberti KGMM, et al. Circulation, October, 2009
10 Treatment of MetS/IRS Lifestyle intervention is successful (DPS 2002, DPP 2002) Metformin is a well-proven drug that reduces mortality in overweight /obese subjects with DM2 (UKPDS 1998) and can prevent DM2 in IGT subjects (DPP 2002) Glitazones are tested for CVD and DM2 preventive effects with mixed results (Pro-Active, DREAM, RECORD) Antihypertensive drugs should be used without further impairing insulin sensitivity or worsening of metabolic abnormalities
11 Healthy food choices: Mediterranean Diet
12
13 Increased use of natural anti-oxidants
14 Smoking cessation always of great importance! Group sessions Social support Drugs: - NRT - Bupropion - Varenicline INTERHEART study, Lancet 2006
15 Lifestyle intervention for cardiovascular risk reduction in the primary health care setting: 3-year follow-up of the Björknäs study Margareta Eriksson º ¹ ², Carl-Johan Westborg º, Paul W Franks ², Mats Eliasson ² ³ Björknäs Primary Health Care Centre, Boden Sweden, ¹ Department of Community Medicine and Rehabilitation, Umeå University, Sweden, ² Department of Public Health and Clinical Medicine, Umeå University, Sweden, ³ Department of Medicine, Sunderby Hospital, Luleå, Sweden margareta.eriksson@nll.se Eriksson MK, et al. PLoS One. 2009;4(4):e5195.
16 Norrbotten, Sweden Björknäs PHC center in Boden
17 2. Outcomes measures Primary outcomes: Changes in anthropometry, maximal oxygen uptake, health-related quality of life and self-reported physical activity Secondary outcomes: Changes in blood pressure and metabolic variables
18 4. Time axis of the study Intervention Follow-up meetings for the intervention group monthly quarterly semi-annually 0 3 months 1 year 2 year 3 year Examinations
19 5. Intervention I. Exercise Three weekly group sessions of supervised progressive exercise training during the first 3 months. Water aerobics minutes Nordic walking / brisk walking minutes Interval training on a bicycle ergometer minutes and circuit-type resistance training minutes For optimal intensity: Borg RPE Scale % of maximal oxygen uptake
20 6. Intervention II. Diet counselling Five 20-min long group meetings with a dietician Written and verbal information In accordance with the Nordic recommendation In nutrition (NNR) III. Follow-up meetings regularly Led by a physiotherapist or a dietician Strategies used based on the stage.of-change model of behavioural change
21 Participants flow 340 eligible individuals were invited, with Dm, HT or MetS 177 individuals (52%) accepted to participate 151 were randomized, 76 to the control group and 75 to the intervention group 145 were included in Intention-to-treat analyses 74 in the control group and 71 in the intervention group 120 subjects fullfilled the 3-year follow-up. Lost to follow-up18% 21
22 Changes in waist circumference (n=120) Control Intervention *** *** ** *** Changes between groups at independent t-tests * p< 0.05, ** p< 0.01, *** p <
23 Clinical measurements after 3 yrs (ITT n=145) Significant difference between groups: Decrease in waist circumference 2.2 cm Decrease in waist to hip ratio 0.02 Reduction in systolic blood pressure 5.1 mmhg Reduction in diastolic blood pressure 1.6 mmhg Increase in maximal oxygen uptake, VO₂ 0.1 l/m No significant difference between groups in: Weight or Body Mass Index (BMI) 23
24 (mmhg) (mmhg) Changes in blood pressure ITT n=145 Systolic bloodpressure Diastolic blood pressure p-value p-value: * * * * Time Baseline 3 months 1 year 2 years 3 years 82 Time Baseline 3 months 1 year 2 years 3 years Control group Intervention group Control group Intervention group 24
25 (VO₂ l/min) (VO₂ ml/kg/min) Changes in aerobic fitness ITT n=145 Maximal oxygen uptake Maximal oxygen uptake 2,6 31 2,5 ** p-value *** p-value ,4 29 2,3 28 2,2 2, ,9 Time 0 3 m m m m Control group Intervention group 23 Time 0 3 m m m m Control group Intervention group 25
26 Laboratory measurements after 3 yr No significant differences between groups in: Blood lipids Blood glucose, HbA1 c Impaired glucose tolerans: 24% in intervention group, 34% in control group Control group: One new case of diabetes 26
27 Proportion of group Proportion of group Total physical activity A 100% 90% 80% Control group - Total physical activity Repeateed measures p-value < % 90% 80% Intervention group - Total physical activity 70% 70% 60% 50% 40% 30% 20% Very active Moderatly active Minimally active Sedentary 60% 50% 40% 30% 20% Very active Moderatly active Minimally active Sedentary 10% 10% 0% Baseline 3 months 1 year 2 years 3 years 0% Baseline 3 months 1 year 2 years 3 years Study phase Study phase
28 Proportion of group Proportion of group Exercise C 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% Control group - Exercise Baseline 3 months 1 year 2 years 3 years Study phase Repeated measures p-value < >60 min/d min/d <30 min/d None 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% Interventiongroup - Exercise Baseline 3 montths 1 year 2 years 3 years Study phase >60 min/d min/d <30 min/d None
29 Conclusion An inexpensive prevention programme in the primary health care setting with focusing on physical activity and diet counselling and structured follow-up meetings can favourably influence several cardiovascular risk factors in high-risk subjects, which persists for up to three years.
30 Specific Drug Therapy One example Stroke secondary prevention
31 Three men that all died of stroke or its complications
32 Messerli F, N Engl J Med 1995;332:
33 Rehabilitation after CVD event Lifestyle intervention Evidence-based drug therapy Technical interventions Support-groups and active relatives Structures programmes for follow-up
34 Blood Pressure Lowering and Secondary Prevention of Stroke Trials of Antihypertensive Treatment in Patients With Previous Stroke or TIA % 40 Achieved SBP (mmhg) % % % Stroke reduction 120 PATS All Comb 5% Mono 5% PROF 0 PROGRESS Zanchetti et al. J Hypertens 2009; 27:
35 Effects of Blood Pressure Lowering on Fatal and Nonfatal Recurrent Stroke All Studies Trial BP Δ BP Odds Ratios (95% Cl) Recurrent Stroke/Patients All diuretics 153/ 91 Q=5.43 P=0.14 All RAS inhibitors Q=4.56 P= /8 4 FEVER* 160/9 3 Treated Control 9.6/ ( ) 356/ /4867 2P< / ( ) 1227/ 2P= / /1.8 66/ / 1232 All trials 147/8 6 Heterogeneity Q=32.2 P= *FEVER: Felodipine Event Reduction Study 5.1/ ( ) 1649/ 2P= Favors Favors Treatment Control 1916/ Liu et al, Hypertens Res 2009; 32:
36 Statins in Primary Prevention of Stroke Risk of stroke in four statin primary prevention trials Hazard Ratio [95% CI] WOSCOPS AFCAPS/TexCAPS MEGA JUPITER RR: 0.89 [ ] RR: 0.82 [ ] RR: 0.83 [ ] RR: 0.52 [ ] All RR: 0.75 [ ]; p= Statin better Placebo better Everet et al. Circulation 2010; 121:
37 Statins in Secondary Prevention of Stroke: the SPARCL Study 205 centres worldwide Mean age 63 years Stroke or TIA documented 6 previous months 62% with HT and 17% DM-2 No previous CVD Antiplatelet therapy 94% LDL-C levels 100 mg/dl and 190 mg/dl 4,731 patients Double blind period Atorvastatin 80 mg/day Placebo Primary end-point: Time to first fatal and non-fatal stroke The SPARCL Investigators. N Engl J Med. 2006; 355:
38 Statins in Secondary Prevention of Stroke: SPARCL Study Cumulated incidence (%) 8 Fatal and non-fatal stroke Atorvastatin 80 mg Placebo RRR 16% 4 0 P= 0.03 Adjusted RR*= 0.84 [IC 95% ] Time (years) since randomization The SPARCL Investigators. N Engl J Med. 2006; 355:
39 Arterial wall Time course of Early Vascular Ageing (EVA) and possible intervention by Aggressive Decrease of Atherosclerosis Modifiers (ADAM) in CVD risk patients 100% damaged Period of early detection and successful regression ADAM (late stage) ADAM (earlier stage) EVA 100% normal normal vascular aging Time Nilsson PM, Laurent S. et al. Hypertension 2009
40 Summary The Metabolic syndrome (MetS) as a clinical entity has been recognised by clinicians for more than 80 years Even if MetS is not a perfect tool for research it can be used in clinical practice to find risk factor clusters The core effects of AH in MetS is the arterial stiffening and target organ damage, including EVA Lifestyle intervention is part of rehabilitation and synergistic with drug therapy PN 2010
Five chapters 1. What is CVD prevention 2. Why is CVD prevention needed 3. Who needs CVD prevention 4. How is CVD prevention applied 5. Where should CVD prevention be offered Shorter, more adapted to clinical
More informationDiabetes Mellitus: A Cardiovascular Disease
Diabetes Mellitus: A Cardiovascular Disease Nestoras Mathioudakis, M.D. Assistant Professor of Medicine Division of Endocrinology, Diabetes, & Metabolism September 30, 2013 1 The ABCs of cardiovascular
More informationThe Metabolic Syndrome: Is It A Valid Concept? YES
The Metabolic Syndrome: Is It A Valid Concept? YES Congress on Diabetes and Cardiometabolic Health Boston, MA April 23, 2013 Edward S Horton, MD Joslin Diabetes Center Harvard Medical School Boston, MA
More informationThe Clinical Unmet need in the patient with Diabetes and ACS
The Clinical Unmet need in the patient with Diabetes and ACS Professor Kausik Ray (UK) BSc(hons), MBChB, MD, MPhil, FRCP (lon), FRCP (ed), FACC, FESC, FAHA Diabetes is a global public health challenge
More informationTotal risk management of Cardiovascular diseases Nobuhiro Yamada
Nobuhiro Yamada The worldwide burden of cardiovascular diseases (WHO) To prevent cardiovascular diseases Beyond LDL Multiple risk factors With common molecular basis The Current Burden of CVD CVD is responsible
More informationMetabolic Syndrome Update The Metabolic Syndrome: Overview. Global Cardiometabolic Risk
Metabolic Syndrome Update 21 Marc Cornier, M.D. Associate Professor of Medicine Division of Endocrinology, Metabolism & Diabetes University of Colorado Denver Denver Health Medical Center The Metabolic
More informationThe JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009
The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain
More informationIschemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010
Ischemic Heart and Cerebrovascular Disease Harold E. Lebovitz, MD, FACE Kathmandu November 2010 Relationships Between Diabetes and Ischemic Heart Disease Risk of Cardiovascular Disease in Different Categories
More informationMarshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona,
Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona, Jamaica At the end of this presentation the participant
More informationGuidelines on cardiovascular risk assessment and management
European Heart Journal Supplements (2005) 7 (Supplement L), L5 L10 doi:10.1093/eurheartj/sui079 Guidelines on cardiovascular risk assessment and management David A. Wood 1,2 * 1 Cardiovascular Medicine
More informationOptimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden
Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden Cardiovascular Disease Prevention (CVD) Three Strategies for CVD
More informationThe Diabetes Link to Heart Disease
The Diabetes Link to Heart Disease Anthony Abe DeSantis, MD September 18, 2015 University of WA Division of Metabolism, Endocrinology and Nutrition Oswald Toosweet Case #1 68 yo M with T2DM Diagnosed DM
More informationThe target blood pressure in patients with diabetes is <130 mm Hg
Controversies in hypertension, About Diabetes diabetes and and metabolic Cardiovascular syndrome Risk ESC annual congress August 29, 2011 The target blood pressure in patients with diabetes is
More informationBlood Pressure Targets in Diabetes
Stockholm, 29 th August 2010 ESC Meeting Blood Pressure Targets in Diabetes Peter M Nilsson, MD, PhD Department of Clinical Sciences University Hospital, Malmö Sweden Studies on BP in DM2 ADVANCE RCT (Lancet
More informationThe Metabolic Syndrome Update The Metabolic Syndrome Update. Global Cardiometabolic Risk
The Metabolic Syndrome Update 2018 Marc Cornier, M.D. Professor of Medicine Division of Endocrinology, Metabolism & Diabetes Anschutz Health and Wellness Center University of Colorado School of Medicine
More informationEugene Barrett M.D., Ph.D. University of Virginia 6/18/2007. Diagnosis and what is it Glucose Tolerance Categories FPG
Diabetes Mellitus: Update 7 What is the unifying basis of this vascular disease? Eugene J. Barrett, MD, PhD Professor of Internal Medicine and Pediatrics Director, Diabetes Center and GCRC Health System
More informationDyslipidaemia. Is there any new information? Dr. A.R.M. Saifuddin Ekram
Dyslipidaemia Is there any new information? Dr. A.R.M. Saifuddin Ekram PhD,FACP,FCPS(Medicine) Professor(c.c.) & Head Department of Medicine Rajshahi Medical College Rajshahi-6000 New features of ATP III
More informationCase Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer
Case Presentation Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer Case Presentation 50 YO man NSTEMI treated with PCI 1 month ago Medical History: Obesity: BMI 32,
More informationDiabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable?
Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable? Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of
More informationYuqing Zhang, M.D., FESC Department of Cardiology, Fu Wai Hospital. CAMS & PUMC, Beijing, China
What Can We Learn from the Observational Studies and Clinical Trials of Prehypertension? Yuqing Zhang, M.D., FESC Department of Cardiology, Fu Wai Hospital. CAMS & PUMC, Beijing, China At ARIC visit 4
More informationESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES
ESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES Pr. Michel KOMAJDA Institute of Cardiology - IHU ICAN Pitie Salpetriere Hospital - University Pierre and Marie Curie, Paris (France) DEFINITION A
More informationLDL cholesterol and cardiovascular outcomes?
LDL cholesterol and cardiovascular outcomes? Prof Kausik Ray, BSc (hons), MBChB, FRCP, MD, MPhil (Cantab), FACC, FESC Professor of Cardiovascular Disease Prevention St Georges University of London Honorary
More informationCase Study: Chris Arden. Peripheral Arterial Disease
Case Study: Chris Arden Peripheral Arterial Disease Patient Presentation Diane is a 65-year-old retired school teacher She complains of left calf pain when walking 50 metres; the pain goes away after she
More informationImplementing Type 2 Diabetes Prevention Programmes
Implementing Type 2 Diabetes Prevention Programmes Jaakko Tuomilehto Department of Public Health University of Helsinki Helsinki, Finland FIN-D2D Survey 2004 Prevalence of previously diagnosed and screen-detected
More informationSIGN 149 Risk estimation and the prevention of cardiovascular disease. Quick Reference Guide July Evidence
SIGN 149 Risk estimation and the prevention of cardiovascular disease Quick Reference Guide July 2017 Evidence ESTIMATING CARDIOVASCULAR RISK R Individuals with the following risk factors should be considered
More information1/28/2014. The Metabolic Syndrome: Early History. Insulin Resistance: Early Diagnosis and Treatment to Prevent Cardiovascular Disease
: Early Diagnosis and Treatment to Prevent Cardiovascular Disease Henry N. Ginsberg, M.D. Irving Professor of Medicine Columbia University College of Physicans and Surgeons The Metabolic Syndrome: Early
More informationThe Metabolic Syndrome Update The Metabolic Syndrome: Overview. Global Cardiometabolic Risk
Update 2013 Marc Cornier, M.D. Associate Professor of Medicine Division of Endocrinology, Metabolism & Diabetes Anschutz Health and Wellness Center University of Colorado School of Medicine Denver Health
More informationJohn J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam
Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention
More informationATP IV: Predicting Guideline Updates
Disclosures ATP IV: Predicting Guideline Updates Daniel M. Riche, Pharm.D., BCPS, CDE Speaker s Bureau Merck Janssen Boehringer-Ingelheim Learning Objectives Describe at least two evidence-based recommendations
More informationA factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes
A factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes Hypotheses: Among individuals with type 2 diabetes, the risks of major microvascular
More informationHow to Reduce CVD Complications in Diabetes?
How to Reduce CVD Complications in Diabetes? Chaicharn Deerochanawong M.D. Diabetes and Endocrinology Unit Department of Medicine Rajavithi Hospital, Ministry of Public Health Framingham Heart Study 30-Year
More informationCardiovascular Complications of Diabetes
VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary
More information1. Albuminuria an early sign of glomerular damage and renal disease. albuminuria
1. Albuminuria an early sign of glomerular damage and renal disease albuminuria Cardio-renal continuum REGRESS Target organ damage Asymptomatic CKD New risk factors Atherosclerosis Target organ damage
More information9/29/2015. Primary Prevention of Heart Disease: Objectives. Objectives. What works? What doesn t?
Primary Prevention of Heart Disease: What works? What doesn t? Samia Mora, MD, MHS Associate Professor, Harvard Medical School Associate Physician, Brigham and Women s Hospital October 2, 2015 Financial
More informationDiabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology
Diabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology Disclosures In compliance with the accrediting board policies, the American Diabetes Association requires the
More informationThe Burden of the Diabetic Heart
The Burden of the Diabetic Heart Dr. Ghaida Kaddaha (MBBS, MRCP-UK, FRCP-london) Diabetes Unit Rashid Hospital Dubai U.A.E Risk of CVD in Diabetes Morbidity and mortality from CVD is 2-4 fold higher than
More informationBranko N Huisa M.D. Assistant Professor of Neurology UNM Stroke Center
Branko N Huisa M.D. Assistant Professor of Neurology UNM Stroke Center THE END! CHANGABLE Blood pressure Diabetes Mellitus Hyperlipidemia Atrial fibrillation Nicotine Drug abuse Life style NOT CHANGABLE
More informationDisclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease
Disclosures Diabetes and Cardiovascular Risk Management Tony Hampton, MD, MBA Medical Director Advocate Aurora Operating System Advocate Aurora Healthcare Downers Grove, IL No conflicts or disclosures
More informationJUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study
Panel Discussion: Literature that Should Have an Impact on our Practice: The Study Kaiser COAST 11 th Annual Conference Maui, August 2009 Robert Blumberg, MD, FACC Ralph Brindis, MD, MPH, FACC Primary
More informationMetabolic Syndrome: What s in a name?
Commentary Metabolic Syndrome: What s in a name? Deborah P. Wubben, MD, MPH; Alexandra K. Adams, MD, PhD Abstract The term metabolic syndrome has recently become en vogue. But is the definition realistic,
More information5/28/2010. Pre Test Question
Myth of Metabolic Syndrome? C. W. Spellman, DO, PhD Professor and Associate Dean Research Dir. Center Diabetes and Metabolic Disorders Department Internal Medicine, Div. Endocrinology Texas Tech University
More informationIra S. Ockene, M.D. David and Barbara Milliken Professor of Preventive Cardiology University of Massachusetts Medical School
Cardiovascular Disease: how did it become such a problem, what are the risk factors with particular emphasis on diabetes and obesity, and how public policy work can to improve the health of all Ira S.
More informationCardiovascular Complications in Diabetes
What is all the fuss about? Cardiovascular Complications in Diabetes Dina Shrestha MD Consultant Endocrinologist Norvic International Hospital and Medical College Hospital for Advanced Medicine and Surgery
More informationValue of cardiac rehabilitation Prof. Dr. L Vanhees
Session: At the interface of hypertension and coronary heart disease haemodynamics, heart and hypertension Value of cardiac rehabilitation Prof. Dr. L Vanhees ESC Stockholm August 2010 Introduction There
More informationHSN301 REVISION NOTES TOPIC 1 METABOLIC SYNDROME
HSN301 REVISION NOTES TOPIC 1 METABOLIC SYNDROME What does the term Metabolic Syndrome describe? Metabolic syndrome describes a cluster of cardio-metabolic conditions that increase one's risk of developing
More informationThe Latest Generation of Clinical
The Latest Generation of Clinical Guidelines: HTN and HLD Dave Brackett Clinical Guideline Purpose Uniform approach Awareness of key details Diagnosis Treatment Monitoring Evidence based approach Inform
More informationMacrovascular Residual Risk. What risk remains after LDL-C management and intensive therapy?
Macrovascular Residual Risk What risk remains after LDL-C management and intensive therapy? Defining Residual Vascular Risk The risk of macrovascular events and microvascular complications which persists
More informationHow to Reduce Residual Risk in Primary Prevention
How to Reduce Residual Risk in Primary Prevention Helene Glassberg, MD Assistant Professor of Medicine Section of Cardiology Hospital of the University of Pennsylvania Philadelphia, PA USA Patients with
More informationDyslipidemia in women: Who should be treated and how?
Dyslipidemia in women: Who should be treated and how? Lale Tokgozoglu, MD, FACC, FESC Professor of Cardiology Hacettepe University Faculty of Medicine Ankara, Turkey. Cause of Death in Women: European
More informationMetabolic Syndrome.
www.bmiweightloss.com.au What is the metabolic syndrome? The was first described in 1988 by Gerald Reavson It was originally described as the clustering of four conditions These conditions when present
More informationInflammation and and Heart Heart Disease in Women Inflammation and Heart Disease
Inflammation and Heart Disease in Women Inflammation and Heart Disease What is the link between een inflammation and atherosclerotic disease? What is the role of biomarkers in predicting cardiovascular
More informationThe Metabolic Syndrome
The Metabolic Syndrome Advances in Internal Medicine David D. Waters, MD May 21, 27 UCSF Metabolic Syndrome: Definition abdominal obesity increased waist circumference atherogenic dyslipidemia low HDL-C,
More informationExercise Studies Where Walking is Better than Running: Does Intensity Matter?
Exercise Studies Where Walking is Better than Running: Does Intensity Matter? Frontiers in Medicine The Forest 24 September 2018 William E. Kraus, M.D. Exercise Intensity and Volume Effects: Confounded?
More informationCLINICAL OUTCOME Vs SURROGATE MARKER
CLINICAL OUTCOME Vs SURROGATE MARKER Statin Real Experience Dr. Mostafa Sherif Senior Medical Manager Pfizer Egypt & Sudan Objective Difference between Clinical outcome and surrogate marker Proper Clinical
More informationPrevenzione cardiovascolare e cambiamento degli stili di vita. Gian Franco Gensini
Prevenzione cardiovascolare e cambiamento degli stili di vita Gian Franco Gensini Main causes of death worldwide at all ages (year:: 2005) 17.5 milion Preventing Chronic Diseases A vital investiment. WHO
More informationCedars Sinai Diabetes. Michael A. Weber
Cedars Sinai Diabetes Michael A. Weber Speaker Disclosures I disclose that I am a Consultant for: Ablative Solutions, Boston Scientific, Boehringer Ingelheim, Eli Lilly, Forest, Medtronics, Novartis, ReCor
More informationTreatment of Cardiovascular Risk Factors. Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center
Treatment of Cardiovascular Risk Factors Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center Disclosures: None Objectives What do risk factors tell us What to check and when Does treatment
More informationPreventing Diabetes K A R O L E. W A T S O N, M D, P H D, F A C C P R O F E S S O R O F M E D I C I N E / C A R D I O L O G Y
Preventing Diabetes 2018 K A R O L E. W A T S O N, M D, P H D, F A C C P R O F E S S O R O F M E D I C I N E / C A R D I O L O G Y D A V I D G E F F E N S C H O O L O F M E D I C I N E A T U C L A CO-DIRECTOR,
More informationKnow Your Number Aggregate Report Single Analysis Compared to National Averages
Know Your Number Aggregate Report Single Analysis Compared to National s Client: Study Population: 2242 Population: 3,000 Date Range: 04/20/07-08/08/07 Version of Report: V6.2 Page 2 Study Population Demographics
More informationFasting or non fasting?
Vascular harmony Robert Chilton Professor of Medicine University of Texas Health Science Center Director of Cardiac Catheterization labs Director of clinical proteomics Which is best to measure Lower continues
More informationShould we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway
Should we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway The Polypill A strategy to reduce cardiovascular disease by
More informationThe role of physical activity in the prevention and management of hypertension and obesity
The 1 st World Congress on Controversies in Obesity, Diabetes and Hypertension (CODHy) Berlin, October 26-29 2005 The role of physical activity in the prevention and management of hypertension and obesity
More informationDiscussion points. The cardiometabolic connection. Cardiometabolic Risk Management in the Primary Care Setting
Session #5 Cardiometabolic Risk Management in the Primary Care Setting Sonja Reichert, MD MSc FCFP FACPM Betty Harvey, RNEC BScN MScN Amanda Mikalachki, RN BScN CDE S Discussion points Whom should we be
More informationsurtout qui n est PAS à risque?
3*25 min et surtout qui n est PAS à risque? 2018 ESC/ESH Hypertension Guidelines 2018 ESC-ESH Guidelines for the Management of Arterial Hypertension 28 th ESH Meeting on Hypertension and Cardiovascular
More informationROLE OF INFLAMMATION IN HYPERTENSION. Dr Barasa FA Physician Cardiologist Eldoret
ROLE OF INFLAMMATION IN HYPERTENSION Dr Barasa FA Physician Cardiologist Eldoret Outline Inflammation in CVDs the evidence Basic Science in Cardiovascular inflammation: The Main players Inflammation as
More informationCVD Risk Assessment. Michal Vrablík Charles University, Prague Czech Republic
CVD Risk Assessment Michal Vrablík Charles University, Prague Czech Republic What is Risk? A cumulative probability of an event, usually expressed as percentage e.g.: 5 CV events in 00 pts = 5% risk This
More informationHypertension and obesity. Dr Wilson Sugut Moi teaching and referral hospital
Hypertension and obesity Dr Wilson Sugut Moi teaching and referral hospital No conflict of interests to declare Obesity Definition: excessive weight that may impair health BMI Categories Underweight BMI
More informationRisk Factors for Heart Disease
Risk Factors for Heart Disease Risk Factors we cannot change (Age, Gender, Family History) Risk Factors we can change (modifiable) Smoking Blood pressure Cholesterol Diabetes Inactivity Overweight Stress
More informationGuidelines for Integrated Management of. Cardiovascular Diseases and Diabetes. in Clinics and Ri-hospitals
Guidelines for Integrated Management of Cardiovascular Diseases and Diabetes in Clinics and Ri-hospitals Ministry of Public Health DPR Korea January 2013 Rationale ncommunicable diseases such as cardiovascular
More informationAntihypertensive Trial Design ALLHAT
1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes
More informationMacrovascular Disease in Diabetes
Macrovascular Disease in Diabetes William R. Hiatt, MD Professor of Medicine/Cardiology University of Colorado School of Medicine President, CPC Clinical Research Conflicts CPC Clinical Research (University-based
More informationComplications of Diabetes mellitus. Dr Bill Young 16 March 2015
Complications of Diabetes mellitus Dr Bill Young 16 March 2015 Complications of diabetes Multi-organ involvement 2 The extent of diabetes complications At diagnosis as many as 50% of patients may have
More informationIdentification of subjects at high risk for cardiovascular disease
Master Class in Preventive Cardiology Focus on Diabetes and Cardiovascular Disease Geneva April 14 2011 Identification of subjects at high risk for cardiovascular disease Lars Rydén Karolinska Institutet
More informationCardiovascular Management of a Patient with Diabetes
Cardiovascular Management of a Patient with Diabetes Dr Jeremy Krebs Clinical Leader Endocrinology and Diabetes Wellington Hospital Summary People with diabetes take a lot of medication Compliance and
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE QUALITY AND OUTCOMES FRAMEWORK (QOF) INDICATOR DEVELOPMENT PROGRAMME Briefing paper QOF indicator area: Peripheral arterial disease Potential output:
More informationReview of guidelines for management of dyslipidemia in diabetic patients
2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University
More informationTailored Statin Treatment for Type 2 Diabetes. Han, Ki Hoon Asan Medical Center University of Ulsan
Tailored Statin Treatment for Type 2 Diabetes Han, Ki Hoon Asan Medical Center University of Ulsan 1 Cardiovascular disease ; No1. death (2001) respiratory tract infection Other NCD S HIV/AIDS deaths during
More informationALLHAT. Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic
1 U.S. Department of Health and Human Services National Institutes of Health Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker
More informationModelling Reduction of Coronary Heart Disease Risk among people with Diabetes
Modelling Reduction of Coronary Heart Disease Risk among people with Diabetes Katherine Baldock Catherine Chittleborough Patrick Phillips Anne Taylor August 2007 Acknowledgements This project was made
More informationDysglycaemia and Hypertension. Dr E M Manuthu Physician Kitale
Dysglycaemia and Hypertension Dr E M Manuthu Physician Kitale None Disclosures DM is MI equivalent MR FIT Objective was to assess predictors of CVD mortality among men with and without diabetes and
More informationEnvironmental. Vascular / Tissue. Metabolics
Global Risk Reduction--WINS Picking Mom and Dad-2016 Environmental Vascular / Tissue Metabolics Stop smoking-1b Physical activity-1b Weight control-1b Chelation therapy-3c Influenza vaccination-1b Blood
More informationThe American Diabetes Association estimates
DYSLIPIDEMIA, PREDIABETES, AND TYPE 2 DIABETES: CLINICAL IMPLICATIONS OF THE VA-HIT SUBANALYSIS Frank M. Sacks, MD* ABSTRACT The most serious and common complication in adults with diabetes is cardiovascular
More informationStatin therapy in patients with Mild to Moderate Coronary Stenosis by 64-slice Multidetector Coronary Computed Tomography
Statin therapy in patients with Mild to Moderate Coronary Stenosis by 64-slice Multidetector Coronary Computed Tomography Hyo Eun Park 1, Eun-Ju Chun 2, Sang-Il Choi 2, Soyeon Ahn 2, Hyung-Kwan Kim 3,
More informationStatins for Cardiovascular Disease Prevention in Women: Review of the Evidence
Statins for Cardiovascular Disease Prevention in Women: Review of the Evidence Karen E. Aspry, M.D., M.S., ABCL, FACC Assistant Professor of Medicine (Clinical) Alpert Medical School of Brown University
More information김광일 서울대학교의과대학내과학교실 분당서울대학교병원내과
치매예방을위한만성질환관리전략 김광일 서울대학교의과대학내과학교실 분당서울대학교병원내과 A sharp rise in the death rate from Alzheimer s disease Ivan Casserly & Eric Topol, Lancet 2004 Potential for primary prevention of Alzheimer s disease Alzheimer
More informationTreatment to reduce cardiovascular risk: multifactorial management
Treatment to reduce cardiovascular risk: multifactorial management Matteo Anselmino, MD PhD Assistant Professor San Giovanni Battista Hospital Division of Cardiology, Department of Internal Medicine University
More informationContents. I. CV disease and insulin resistance: Challenges and opportunities. II. Insulin sensitizers: Surrogate and clinical outcomes studies
Contents I. CV disease and insulin resistance: Challenges and opportunities II. Insulin sensitizers: Surrogate and clinical outcomes studies IV. Identifying and treating patients with insulin resistance
More informationLessons from Recent Atherosclerosis Trials
Lessons from Recent Atherosclerosis Trials Han, Ki Hoon MD PhD Asan Medical Center Seoul, Korea Change of concept Primary vs. secondary prevention Low risk vs. High risk High Risk CHD and equivalents CHD
More informationProfessor Norman Sharpe. Heart Foundation West Coast
Professor Norman Sharpe Heart Foundation West Coast Primary Care the Keystone to Heart Health Improvement Norman Sharpe June 2013 The heart health continuum and the keystone position The culprit disease
More informationWhy is Earlier and More Aggressive Treatment of T2 Diabetes Better?
Blood glucose (mmol/l) Why is Earlier and More Aggressive Treatment of T2 Diabetes Better? Disclosures Dr Kennedy has provided CME, been on advisory boards or received travel or conference support from:
More informationHypertension with Comorbidities Treatment of Metabolic Risk Factors in Children and Adolescents
Hypertension with Comorbidities Treatment of Metabolic Risk Factors in Children and Adolescents Stella Stabouli Ass. Professor Pediatrics 1 st Department of Pediatrics Hippocratio Hospital Evaluation of
More informationCardiovascular disease and diabetes Vascular harmony
Cardiovascular disease and diabetes 2018 Vascular harmony Robert Chilton Professor of Medicine University of Texas Health Science Center Director of Cardiac Catheterization labs Director of clinical proteomics
More informationAssociation between arterial stiffness and cardiovascular risk factors in a pediatric population
+ Association between arterial stiffness and cardiovascular risk factors in a pediatric population Maria Perticone Department of Experimental and Clinical Medicine University Magna Graecia of Catanzaro
More informationBest Lipid Treatments
Best Lipid Treatments Pam R. Taub MD, FACC Director of Step Family Cardiac Rehabilitation and Wellness Center Associate Professor of Medicine UC San Diego Health System Overview of Talk Review of pathogenesis
More informationNew Antihypertensive Strategies to Improve Blood Pressure Control
New Antihypertensive Strategies to Improve Blood Pressure Control Antonio Coca, MD, PhD,, FRCP, FESC Hypertension and Vascular Risk Unit Department of Internal Medicine. Hospital Clínic (IDIBAPS) University
More informationHeart Disease Genesis
Heart Disease Genesis The Ultimate Lecture on CAD origins Petr Polasek MD FRCPC FACC Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored,
More information5/2/2016. Outpatient Stroke Management Sheila Smith MD May 5, 2016
Outpatient Stroke Management Sheila Smith MD May 5, 2016 1 Management of Outpatient Stroke Objectives Review blood pressure management post stroke Review antithrombotic therapy Review statin therapy Discuss
More informationADVANCE post trial ObservatioNal Study
Hot Topics in Diabetes 50 th EASD, Vienna 2014 ADVANCE post trial ObservatioNal Study Sophia Zoungas The George Institute The University of Sydney Rationale and Study Design Sophia Zoungas The George Institute
More informationTerm-End Examination December, 2009 MCC-006 : CARDIOVASCULAR EPIDEMIOLOGY
MCC-006 POST GRADUATE DIPLOMA IN CLINICAL CARDIOLOGY (PGDCC) 00269 Term-End Examination December, 2009 MCC-006 : CARDIOVASCULAR EPIDEMIOLOGY Time : 2 hours Maximum Marks : 60 Note : There will be multiple
More informationHeart Outcomes Prevention Evaluation (HOPE) - 3 Combined Lipid Lowering and Blood Pressure Lowering in Moderate Risk People
November September 23, 20, 20102012 Heart Outcomes Prevention Evaluation (HOPE) - 3 Combined Lipid Lowering and Blood Pressure Lowering in Moderate Risk People Eva Lonn, Jackie Bosch, Jane Castelli, Andrea
More information